Zimmer Biomet Holdings Inc (NYSE:ZBH) was the recipient of some unusual options trading on Friday. Investors acquired 1,169 put options on the stock. This is an increase of 1,480% compared to the average daily volume of 74 put options.

ZBH has been the subject of several analyst reports. Deutsche Bank raised Zimmer Biomet from a “hold” rating to a “buy” rating and set a $128.00 price objective for the company in a report on Tuesday, November 14th. Edward Jones raised Zimmer Biomet from a “hold” rating to a “buy” rating in a report on Thursday, November 9th. Gabelli initiated coverage on Zimmer Biomet in a report on Thursday, August 24th. They set a “buy” rating and a $142.00 price target for the company. SunTrust Banks set a $136.00 price target on Zimmer Biomet and gave the stock a “buy” rating in a report on Wednesday, November 1st. Finally, Jefferies Group reissued a “buy” rating and set a $136.00 price target on shares of Zimmer Biomet in a report on Friday, November 3rd. Three analysts have rated the stock with a sell rating, seven have assigned a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $133.57.

Institutional investors and hedge funds have recently modified their holdings of the business. Bronfman E.L. Rothschild L.P. increased its holdings in Zimmer Biomet by 25.3% in the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 827 shares of the medical equipment provider’s stock worth $106,000 after purchasing an additional 167 shares in the last quarter. Bank of Nova Scotia Trust Co. acquired a new position in Zimmer Biomet in the 3rd quarter worth about $112,000. FNY Managed Accounts LLC acquired a new position in Zimmer Biomet in the 3rd quarter worth about $117,000. Steward Partners Investment Advisory LLC acquired a new position in Zimmer Biomet in the 3rd quarter worth about $140,000. Finally, BB&T Investment Services Inc. bought a new stake in shares of Zimmer Biomet in the 2nd quarter valued at about $144,000. 85.92% of the stock is owned by institutional investors and hedge funds.

Zimmer Biomet (ZBH) opened at $121.38 on Wednesday. Zimmer Biomet has a fifty-two week low of $100.87 and a fifty-two week high of $133.49. The company has a debt-to-equity ratio of 0.88, a current ratio of 1.47 and a quick ratio of 0.78. The stock has a market capitalization of $23,333.00, a PE ratio of 14.28, a price-to-earnings-growth ratio of 1.79 and a beta of 1.15.

Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Wednesday, November 1st. The medical equipment provider reported $1.72 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.74 by ($0.02). Zimmer Biomet had a return on equity of 16.29% and a net margin of 8.36%. The firm had revenue of $1.82 billion during the quarter, compared to analyst estimates of $1.83 billion. During the same period in the previous year, the company earned $1.79 EPS. Zimmer Biomet’s revenue for the quarter was down .8% on a year-over-year basis. equities analysts forecast that Zimmer Biomet will post 8.03 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Monday, January 29th. Shareholders of record on Friday, December 29th will be issued a $0.24 dividend. The ex-dividend date is Thursday, December 28th. This represents a $0.96 dividend on an annualized basis and a yield of 0.79%. Zimmer Biomet’s payout ratio is presently 30.19%.

ILLEGAL ACTIVITY WARNING: “Zimmer Biomet Target of Unusually High Options Trading (ZBH)” was published by Watch List News and is the property of of Watch List News. If you are reading this news story on another website, it was stolen and republished in violation of U.S. and international trademark and copyright legislation. The legal version of this news story can be read at https://www.watchlistnews.com/zimmer-biomet-target-of-unusually-high-options-trading-zbh/1773699.html.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.